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The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces
plasma glucagon concentration in cats
Abstract
Glucagon-like peptide-1 (GLP-1) analogues and inhibitors of its degrading enzyme, dipeptidyl peptidase
IV (DPPIV), are interesting therapy options in human diabetics because they increase insulin secretion
and reduce postprandial glucagon secretion. Given the similar pathophysiology of human type 2 and
feline diabetes mellitus, this study investigated whether the DPPIV inhibitor NVP-DPP728 reduces
plasma glucagon levels in cats. Intravenous glucose tolerance tests (ivGTT; 0.5g/kg glucose after 12h
fasting) and a meal response test (test meal of 50% of average daily food intake, offered after 24h
fasting) were performed in healthy experimental cats. NVP-DPP728 (0.5-2.5mg/kg IV or SC)
significantly reduced glucagon output in all tests and increased insulin output in the ivGTT. Follow-up
studies will investigate the potential usefulness as therapy in diabetic cats.
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Abstract 14 
Glucagon-like peptide-1 (GLP-1) analogues and inhibitors of its degrading enzyme, 15 
dipeptidyl peptidase IV (DPPIV), are interesting therapy options in human diabetics because 16 
they increase insulin secretion and reduce postprandial glucagon secretion. Given the similar 17 
pathophysiology of human type 2 and feline diabetes mellitus, we investigated whether the 18 
DPPIV inhibitor NVP-DPP728 reduces plasma glucagon levels in cats. We performed 19 
intravenous (IV) glucose tolerance tests (ivGTT; 0.5g/kg glucose after 12h fasting) and a meal 20 
response test (test meal of 50% of average daily food intake, offered after 24h fasting) in healthy 21 
experimental cats. NVP-DPP728 (0.5 – 2.5 mg/kg IV or SC) significantly reduced glucagon 22 
output in all tests and increased insulin output in the ivGTT. Follow-up studies will investigate 23 
the potential usefulness for therapy in diabetic cats. 24 
 25 
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Diabetes mellitus is one of the most common endocrinopathies in cats. Current treatment 28 
mainly relies on insulin and feeding low carbohydrate diets. Effective lowering of blood glucose 29 
levels requires aggressive insulin therapy, bearing the risk of insulin-induced hypoglycemia. 30 
Glucagon-like peptide-1 (GLP-1) is released by endocrine intestinal cells in response to eating. 31 
GLP-1 is an interesting treatment option in type 2 diabetics because it potentiates glucose-32 
induced insulin secretion, improves beta-cell proliferation, reduces beta-cell apoptosis and also 33 
decreases postprandial glucagon secretion. GLP-1’s effects are blunted in hypoglycemia, 34 
therefore avoiding dangerously low glucose levels (Nauck, 1998; Holst, 2002; Nielsen et al., 35 
2004). Endogenous GLP-1 is degraded rapidly by dipeptidyl peptidase IV (DPPIV). Its half-life 36 
in rodents is 1–1.5 min (Nauck, 1998). GLP-1 action can be enhanced by delaying its 37 
degradation using DPPIV inhibitors, such as NVP-DPP728 (1-[2-[5-cyanopyridin-2-38 
yl)amino]ethylamino] acetyl-2-cyano-(S)-pyrrolidide monohydrochloride) (Balkan et al., 1999). 39 
 40 
Hyperglucagonemia is a metabolic hallmark in human type 2 diabetics (Ritzel et al., 41 
1995; Holst, 2002) but also diabetic cats (Tschuor et al., 2006). We therefore investigated if 42 
NVP-DPP728 reduces plasma glucagon in cats. The doses (0.5 – 2.5 mg/kg) were adapted from 43 
effective doses in rodents and humans (Ahren et al., 2002; Ahren and Hughes, 2005). Blood 44 
glucose and insulin were also measured because GLP-1 increases glucose-induced insulin 45 
secretion in rodents and humans (Nauck, 1998; Holst, 2002; Nielsen et al., 2004). 46 
 47 
All procedures were approved by the Veterinary Office Zurich. Twelve healthy male 48 
castrated domestic short-hair cats (Harlan; 16-24 months old, body weight 4.9 ± 0.4 kg) were 49 
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kept under a 12 h light/dark cycle and fed canned food (Purina Veterinary Diet: Diabetes 50 
Management, Nestlé Purina) twice daily to maintain stable body weight. Cats were sedated with 51 
ketamine (Ketaminol, Veterinaria; 5-7 mg/kg, IM) and midazolam (Dormicum, Roche; 0.2 52 
mg/kg, IM), followed by propofol anesthesia (Propofol, Fresenius Kabi; 6-7 mg/kg, IV) to 53 
implant a jugular catheter (Seldinger, 1953). Cats were subjected to two intravenous (IV) glucose 54 
tolerance tests (ivGTT) and a meal response test. All tests were performed with six cats using a 55 
cross-over design and 4 weeks between trials.  56 
 57 
Blood glucose was measured with an automated photometric test (COBAS MIRA, 58 
Roche). Insulin and glucagon were measured in EDTA plasma containing aprotinine (Trasylol, 59 
Bayer; 500KIU/mL plasma), by radioimmunoassay (RIA) (insulin: Linco Porcine Insulin RIA 60 
Kit; glucagon: ICN Biomedicals) validated before use (Zini et al., in press). Area under the curve 61 
(AUC) was calculated above baseline of each animal. This was used to compute average AUC. 62 
Values are given as mean ± SEM. Experiments were analyzed by paired Student’s t-tests with P 63 
< 0.05 considered significant.  64 
 65 
Cats were fasted overnight before ivGTT. After basal blood sample, saline or NVP-66 
DPP728 (dissolved in saline) were injected IV (0.5 mg/kg). In a second experiment saline or 67 
NVP-DPP728 were injected subcutaneously (SC; 1mg/kg). Thirty min (IV) or 40 min (SC) later, 68 
D-glucose (0.5 g/kg; 50% dextrose solution, Kantonsapotheke Zürich, Switzerland) was injected 69 
over 30 s via the jugular catheter. A lower dose of glucose was used than recommended to 70 
achieve maximal insulin secretion (Hoenig et al., 2002) to test whether inhibition of GLP-1 71 
degradation further increases glucose-induced insulin secretion. Eight blood samples were 72 
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obtained from 3 to 180 min after glucose. In the first test, plasma glucose in controls increased 73 
from 4.6 ± 0.2 mmol/L to 27.6 ± 3.5 mmol/L 3 min after glucose administration. Glucose levels 74 
and time course were unaffected by NVP-DPP728 (0.5 mg/kg IV). Insulin peaked 15 min after 75 
glucose (37.4 ± 5.8 µIU/mL versus 9.2 ± 0.5 µIU/mL [baseline]). Total insulin output (AUC) 76 
over 15 min increased significantly (P < 0.05) by about 20% by NVP-DPP728. Glucose time-77 
dependently decreased plasma glucagon with the lowest level reached after 3 min (214 ± 30 78 
pg/mL versus 367 ± 65 pg/mL [baseline]). This decrease was stronger after NVP-DPP728 (201 ± 79 
29 pg/mL versus 471 ± 85 pg/mL [baseline]). Overall, NVP-DPP728 significantly reduced 80 
glucagon output (Fig. 1). 81 
 82 
In the second ivGTT, glucose increased from 4.4 ± 0.1 mmol/L to 28.9 ± 4.6 mmol/L 3 83 
min after injection. Insulin peaked 15 min after glucose (36.8 ± 5.5 µIU/mL versus 8.6 ± 0.4 84 
µIU/mL [baseline]). Insulin output (AUC over 15 min) increased significantly (P < 0.05) by 85 
about 25% after NVP-DPP728 (1 mg/kg SC). Glucose significantly decreased plasma glucagon. 86 
This was significantly more pronounced after NVP-DPP728 (Fig. 1). 87 
  88 
Cats were fasted for 24 h before the meal response test. After basal blood sample, saline 89 
or NVP-DPP728 (2.5 mg/kg) were injected SC. Pilot tests indicated that a higher dose of NVP-90 
DPP728 is necessary than during ivGTT, possibly because glucose may be a stronger acute 91 
stimulus for the pancreas than a meal. Forty min later, the test meal (50% of average daily food 92 
intake) was offered which was consumed within 10 min. Blood was sampled at meal ending (0 93 
min) and for the following 5 h, and treated as above. No postprandial hyperglycemia was 94 
present, irrespective of treatment. Insulin was significantly higher (18.7 ± 1.6 µIU/mL versus 8.6 95 
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± 0.4 µIU/mL [baseline]; n = 6) 15 min after meal ending. Total insulin secretion (AUC) was 96 
unaffected by NVP-DPP728. Plasma glucagon significantly increased after the test meal (1 h: 97 
224 ± 32 pg/ml versus 171 ± 29 pg/ml [baseline]). Total glucagon output over 1 h after the test 98 
meal was significantly reduced by NVP-DPP728 (Fig. 2). Despite a clear trend, significance was 99 
not reached at individual time points or for glucagon output over 5 h.  100 
 101 
The present study shows that plasma glucagon in cats was lower after single peripheral 102 
injection of the DPPIV inhibitor NVP-DPP728. This was observed in both ivGTT’s and the meal 103 
response test. Insulin output was increased during the ivGTT. Even though GLP-1 was not 104 
directly measured here due to the lack of a specific assay, we presume that the reduction in 105 
glucagon and increase in insulin by NVP-DPP728 was due to reduced degradation of 106 
endogenous GLP-1, similar to what is known from other species (Balkan et al., 1999).  107 
 108 
GLP-1 reduces glucagon secretion in rodents and humans and normalizes diabetic 109 
hyperglucagonemia (Ritzel et al., 1995; Holst, 2002). We provide indirect evidence that similar 110 
mechanisms may be active in cats because inhibition of DPPIV lowered plasma glucagon under all test 111 
conditions. Because hyperglucagonemia is present in diabetic cats (diabetic cats at baseline: approx. 112 
1300 pg/mL versus 350 pg/mL in healthy controls; Tschuor et al., 2006), our findings suggest that 113 
further studies should test DPPIV inhibitors for the treatment of feline diabetes. Higher doses seem to be 114 
required for SC than IV administration of NVP-DPP728. This may be due to different bioavailability. 115 
DPPIV inhibitors can also be administered orally, but effective doses would have to be tested. 116 
 117 
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Our study has some limitations. First, one may argue that the effects of NVP-DPP728 on 118 
plasma glucagon were rather small and therefore potentially of little relevance. Of note, however, 119 
we used young healthy cats of normal body weight. We believe that the effects of NVP-DPP728 120 
on glucagon may be stronger in diabetic cats because GLP-1’s biological actions generally are 121 
more pronounced during hyperglycemia than during normoglycemia (Nauck, 1998; Nielsen et 122 
al., 2004). This needs to be tested in follow-up studies. Lack of postprandial hyperglycemia may 123 
also explain why NVP-DPP728 did not increase insulin levels during the meal response test. 124 
Second, GLP-1 levels were not directly measured because a specific assay for feline GLP-1 is 125 
not available. Nonetheless, data from other species suggest that NVP-DPP728’s effect relies on 126 
inhibition of GLP-1 degradation. 127 
 128 
In summary, we provide evidence that inhibition of GLP-1 degradation may lower 129 
plasma glucagon in cats. GLP-1 analogues or DPPIV inhibitors may therefore bear therapeutic 130 
potential in diabetic cats. At the doses tested, NVP-DPP728 produced no adverse side effects. 131 
 132 
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Legends to figures 187 
Fig. 1: In two independent experiments, NVP-DPP728 (0.5 mg/kg IV or 1 mg/kg SC; n = 6 for 188 
all groups) significantly reduced plasma glucagon in ivGTT’s in 12 h-fasted cats, as assessed by 189 
AUC during the first 15 min after glucose. * significantly different from respective control (P < 190 
0.05).  191 
 192 
Fig. 2: NVP-DPP728 (2.5 mg/kg SC) significantly reduced plasma glucagon in a meal response 193 
test in six 24 h-fasted cats, as assessed by AUC 1 h after the end of meal. * significantly different 194 
from control (P < 0.05).  195 
 196 
197 
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Fig. 1 197 
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Fig. 2 201 
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